Instead of consulting on a 1% increase in practicing fees, shouldn't we be looking forward to a sizeable drop in the 2019 fee?
After all, the 15 "special projects" and "significant" one-off disciplinary case that were the cause of the 19% increase for the 2018 year will surely have been concluded by then (Pharmacy Council Consultation Document November 2017).
And why does a statutory body like the Pharmacy Council with a captive and compulsory membership base need to carry out two costly PR tours in less than six months?
Thank you for helping New Zealanders attempt to quit smoking with Champix® (varenicline tartrate) over the past decade.
Change is now coming.
From 12 December 2018, the Champix® brand will be replaced by Varenicline Pfizer (varenicline tartrate), and from 1 January 2019 Varenicline Pfizer will be fully funded.1